GGrantIndex
← Leaderboards

Clinton Grubbs

University Of Alabama At Birmingham

Google Scholar ↗PubMed ↗ORCID ↗
$15,915,503
Attributed
$15,915,503
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.2M · FY2009–19
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$15,915,503 · 4

By mechanism

N01$15,915,503 · 4

Top collaborators

No co-investigators on record.

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorMalignant NeoplasmsPreventionChemopreventive AgentTissuesDosePreventivePre-Clinical ModelEvaluationPreventDesignLesionAnimalsMalignant Neoplasm Of Urinary BladderOverexpressionTumorigenesisEfficacy TestingToxic EffectBiological MarkersProteinsIn VitroIn VivoImmunizationBase

Grant awards (18)

FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION$1,052,768
N01 · FY2019 · CA · contact PI
Task Order: Colorectal Cancer Prevention by a Novel EPA Analogue TP-252 and Naproxen in FAP and lynch syndrome models$952,235
N01 · FY2019 · CA · contact PI
Preclinical development of a chemopreventive agent, 4-methylumbelliferone(4-MU) HHSN2512015000361 TORFP: 2018-E07 PP: 9/17/18 to 9/16/19$857,168
N01 · FY2019 · CA · contact PI
TASK ORDER: EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER$615,081
N01 · FY2019 · CA · contact PI
Further Development of Multi-Antigen Vaccines for Primary and Secondary Prevention of Bladder Cancer$231,523
N01 · FY2019 · CA · contact PI
Evaluating Whether a Concurrent Retinoid X Receptor Agonist can Enhance the Efficacy of the HER2-IGFPB2-IGF1R Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Inv$930,464
N01 · FY2018 · CA · contact PI
Prevention of Urinary Bladder Cancer with Two "Clinically-Ready Agents (Everolimus andNaproxen) When Administered in Combination$709,567
N01 · FY2018 · CA · contact PI
EVALUATION OF STAT3 ANTAGONISTS IN THE PREVENTION OF MAMMARY CANCER$678,114
N01 · FY2018 · CA · contact PI
Further Development of Multi-Antigen Vaccines for Primary and Secondary Prevention of Bladder Cancer HHSN2612015000361 TO: HHSN26100011 PP: 9/17/2018 to 3/16/2020$670,206
N01 · FY2018 · CA · contact PI
Preclinical development of a chemopreventive agent, 4-methylumbelliferone(4-MU) HHSN2512015000361 TORFP: 2018-E07 PP: 9/17/18 to 9/16/19$532,854
N01 · FY2018 · CA · contact PI
IGF::OT::IGF EVALUATION OF 'CLINICAL-READY' AGENTS (BAZEDOXIFENE AND LAPATINIB) IN COMBINATION FOR THE PREVENTION OF ER+ AND ER- MAMMARY CANCERSPOP 6/19/2017 - 6/18/2019$767,562
N01 · FY2017 · CA · contact PI
Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder CancerTO POP: 9/15/2017 - 3/14/2019$636,313
N01 · FY2017 · CA · contact PI
R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)$922,642
N01 · FY2016 · CA · contact PI
IGF::OT::IGF EVALUATION OF AGENTS/PROTOCOLS THAT INHIBIT TWO MAJOR PATHWAYS INVOLVED IN HUMAN URINARY BLADDER CANCER(PI3K, EGFR) AND PROTOCOLS TO REDUCE THEIR TOXICITY$679,103
N01 · FY2015 · CA · contact PI
HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma$545,105
N01 · FY2014 · CA · contact PI
HHSN261201200020I/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Task Order Title: Evaluation on the Prevention by Actoplus/Met (Pi$489,093
N01 · FY2014 · CA · contact PI
In vitro and In Vivo screening of chemopreventive agents$399,999
N01 · FY2011 · CA · contact PI
In vitro and In Vivo screening of chemopreventive agents$4,245,706
N01 · FY2009 · CA · contact PI